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There is an increasing demand to determine the clinical implication of experimental findings in molecular
biomedical research. Survival (or failure time) analysis methodologies have been adapted to the analysis of
genomics data to link molecular information with clinical outcomes of interest. Genome-wide molecular profiles
have served as sources for discovery of predictive/prognostic biomarkers as well as therapeutic targets in the past
decade. In this review, we overview currently available software, web applications, and databases specifically developed
for survival analysis in genomics research and discuss issues in assessing clinical utility of molecular features derived
from genomic profiling.
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With the increasing capability to perform genome-wide
molecular characterization of clinical specimens, making
clinical implication of genomic aberrations has become a
more relevant topic. The decreasing cost of the assays
has facilitated accumulation of genomic profiles of sizable
clinical cohorts, with which more reliable molecular prog-
nostic analysis has become possible. Also, expanding clin-
ical contexts covered by the studies/datasets has enabled
exploration of clinically more relevant predictive/prognostic
biomarkers from genomic data [1]. Here, the major interest
is the association of genomic features with clinical out-
comes, including response to certain treatment and prog-
nosis of the patients under specific clinical scenarios.
Clinical outcome especially prognosis is often pre-
sented as the time period between the start and end of
the clinical observation in combination with a binary sta-
tus information, indicating whether or not each patient had
a clinical event of interest, e.g., death, cancer recurrence,
and drug response. In contrast to laboratory experiment-
derived data, clinical outcome data are generally incom-
plete because of the missing observation of the clinical
event. For example, in the case of analyzing time to cancer
recurrence after surgery, some patients who are still recur-
rence free during the study period may develop recurrence
later, i.e., it is uncertain whether the patient should be* Correspondence: yujin.hoshida@mssm.edu
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unless otherwise stated.classified into recurrence-positive or recurrence-negative
group. Such situation, where a true outcome is still un-
known, is treated as a censored observation, and the obser-
vation time is incorporated in the analysis. This type of
analysis is called “survival” or “failure time” analysis, for
which various biostatistical analysis methodologies are
already available. These methodologies have been adapted
for the analysis of genomic datasets with modifications to
accommodate the high-dimensional data structure by util-
izing correction methods for highly multiple hypothesis
testing [2].
The accumulated genomic datasets with clinical out-
come information have led to a new paradigm of bio-
marker research, i.e., in silico discovery and/or validation
of predictive/prognostic molecular biomarkers. In this
article, we overview currently available software, web ap-
plications, and databases specifically developed for inte-
grative analysis of survival and genomic data. We also
discuss current limitations mostly residing on the clinical
study design side and how we could methodologically
overcome these challenges to facilitate the development of
molecular biomarkers with clinical utility.Tools and resources for survival analysis in
genomics research
The major tasks of survival analysis in genomics research
include 1) survey/identify genomic feature(s) correlated
with survival data and 2) evaluate/validate survival data
correlation for predefined genomic feature(s). There are
several freely available tools to complete the tasks for userstd. This is an Open Access article distributed under the terms of the Creative
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(Table 1). Significance Analysis of Microarrays (SAM) is
one of the earliest software to identify genomic feature(s)
correlated with biological and/or clinical phenotypes of
interest, including time-to-event clinical outcome by using
Cox score [3,4]. A similar algorithm is implemented as
modules of the GenePattern software, a generic genomic
data analysis environment and toolkit [5]. GenePattern
LoocvSurvival module enables generation of a robust
prognostic gene signature based on leave-one-out cross-
validation scheme [6]. Cox regression-based method
together with time-dependent receiver operating charac-
teristic (ROC) curve analysis was also reported [7]. Net-
Cox is a method based on Cox regression modeling using
the information of co-regulated multiple genes, which was
reported to improve replication of the prognostic model
[8]. survcomp is an R-based Bioconductor [9] package for
survival risk model comparison based on time-dependent
ROC curve and c index [10].
The ever-expanding repositories of genomic datasets
with clinical outcome information have been serving as re-
sources to build web-based tools/resources for survival-
related genomic analysis (Table 2). NCBI Gene Expression
Omnibus (GEO) [16] and EBI ArrayExpress [17] are
generic databases of a variety of genomic datasets with
or without clinical outcome information. The Cancer
Genome Atlas (TCGA) is a multi-institutional project
generating a wide range of genomic data, which are
made publicly available together with rich clinical anno-
tations including outcome data [18]. Several survival
analysis-focused web applications have also been built
based on these resources. Oncomine is an intensively
curated genomics database with a special focus on
oncology research, providing functionalities of survival-
related analysis for datasets with relevant sample anno-
tations [19]. cBioPortal is a web-based resource that
enables graphical user interface (GUI)-based intuitive
interrogation of a wide range of omics datasets from
TCGA and Cancer Cell Line Encyclopedia (CCLE) [20]
datasets and, when available, survival data analysisTable 1 Software for genomic feature-based survival analysis
Software User interface (programming
Significance Analysis of Microarrays (SAM) Graphical (Excel add-on), comm
GenePatterna Graphical
Partial Cox regression analysis Command-line (R)
Net-Cox Command-line (Matlab)
survcomp Command-line (R)
aSurvivalGene, PrognosticGene, and LoocvSurvival modules deposited in [13].
bSource code available upon request to the authors.including Kaplan-Meier curve and log-rank test [21].
Similar web-based resources combining genomic/clinical
database and analysis tools that enable single/multiple
gene-based prognostic assessment include Kaplan-Meier
Plotter [22], PrognoScan [23], GOBO [24], Recurrence
Online [25], PROGgene [26], bc-GenExMiner [27],
ITTACA [28], SurvExpress [29], and G-DOC Plus [30].
These resources assembled publicly or privately available
datasets from GEO, ArrayExpress, TCGA, and/or private
solicitation/deposition and enable survival analysis based
on prefixed or user-defined cutoff for prognostic sub-
grouping of the patients. Some of them support subgroup
analysis and/or multivariable analysis with clinical prog-
nostic variables when available. Some support survival
classifier based on multiple genes (or gene signature) using
preset algorithms such as averaging or multivariable Cox
regression modeling. Breast Cancer Competition (BCC) is
a collection of tools to facilitate collaborative genomic
classifier building and testing, which was recently used to
develop breast cancer prognostic models based on compe-
tition between multiple data analysis groups [31]. These
tools are readily available to analyze user’s own genes or
survival models in a variety of diseases, tissue types, and
clinical contexts when available.
Toward genome-based biomarkers with real
clinical utility
In silico biomarker validation could be a substantially
more cost-effective strategy for biomarker development,
which typically requires costly and lengthy processes.
Despite the exponentially expanding genomic databases
and associated survival analysis tools and resources, clin-
ically deployed genome-based biomarkers are still scarce,
highlighting the unresolved challenges in biomarker de-
velopment from genomic studies [43]. One major issue
is the clinical study design, which derives the genomic
dataset. Predictive/prognostic biomarkers must follow
predefined specific study plan to demonstrate their val-
idity and clinical utility. In general, such biomarkers and
models should be clearly defined and independentlylanguage) Functionality Reference URL
and-line (R) Feature selection [3,4] [11]
Feature selection, assessment of
survival association, model building
[5] [12,13]
Feature selection, assessment of
survival association, model building
[7] b
Feature selection, assessment of
survival association, model building
[8] [14]
Model comparison [10] [15]
Table 2 Web applications with database for genomic feature-based survival analysis
Web application/database Analyzable genetic feature Covered diseases Reference URL
Oncomine Multiple Cancer [19] [32]
cBioPortal Multiple Cancer (37 types) [21] [33]
Kaplan-Meier Plotter Single Cancer (breast, ovarian, lung) [22] [34]
PrognoScan Single Cancer (14 types) [23] [35]
GOBO Multiple Cancer (breast) [24] [36]
Recurrence online Multiple Cancer (breast) [25] [37]
PROGgene Single/multiple Cancer (21 types) [26] [38]
bc-GenExMiner Single Cancer (breast) [27] [39]
ITTACA Single Cancer (7 types) [28] [40]
SurvExpress Multiple Cancer (20 types) [29] [41]
G-DOC plus Multiple Cancer (9 types), non-cancer (3 types) [30] [42]
Accessed in October 2014.
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lines for assessment of prognostic marker (REMARK)
[44], diagnostic marker (STROBE) [45], and cohort study
(STARD) [46] are available to ensure the quality and val-
idity of the biomarkers. However, a vast majority of
available genomic datasets rarely meet these require-
ments because they were generated by using samples of
convenience, i.e., biospecimens readily available to the
researchers, which were retrospectively collected without
predetermined intention of biomarker development or
assessment. That is, prognostic genes identified through
analysis of the databases may not or less likely to be
clinically reliable or reproducible as biomarkers. Quality
grading for the study design in the genomic databases
such as the one proposed by Simon and colleagues, A
(prospective study), B (retrospective analysis of previous
prospective study samples), C (prospective/observational),
and D (retrospective/observational) [47], will help specu-
late the reliability of the survival analysis result yielded
from each specific dataset. Generation of future genomic
data with special attention on these study design-related
issues will enable highly reliable computational validation
of new biomarkers.
Obviously, the primary goal of this type of exploratory
analysis is to determine or speculate clinical outcome as-
sociation of genomic features. However, if the features
selected through the surveillance are further considered
as candidates for clinical diagnostic development, there
is another issue that needs to be considered. Clinical de-
cision making is generally made according to well-
defined, specific clinical contexts that are often summa-
rized in a diagram or flow chart in the clinical practice
guidelines. For a molecular biomarker to be considered
as a clinical test to support the system of clinical decision
making, the marker must demonstrate clinically meaning-
ful utility in terms of magnitude of benefit, feasibility of
clinical implementation, and cost in association with thesystem of existing clinical decision making system/algo-
rithm. It will be technically feasible to incorporate such
clinical framework in the aforementioned web-based tools
of genomic survival analysis by engaging disease domain
experts in their development.
Clinically applicable molecular biomarkers must
yield reproducible and robust measurements in real-
world clinical setting with clinically acceptable logis-
tical complexity and cost to justify their use. The lack
of reproducibility of the measurement especially for
transcript-based biomarkers has been the major tech-
nical obstacle in clinical deployment of genome-based
biomarkers [48]. Recent development of digital bio-
molecule counting technologies without target amplifi-
cation has been overcoming this challenge by enabling
a more sensitive and robust measurement of a variety
of analytes, including DNA, RNA, and protein, as well
as chemical modifications of these molecules [49].
Assay technologies that are specifically designed to
generate genomic data from real-world clinical speci-
mens, e.g., formalin-fixed paraffin-embedded tissues,
will further expand the informatics resources with rich
clinical contexts/scenarios and enhance our capability
of in silico biomarker research. To accommodate require-
ments from the regulatory agencies for biomarkers such
as FDA in the web-based resources may also help facili-
tate biomarker development. Two additional challenges
in bringing genome-based prognostic biomarkers into
clinics are reimbursement for the assays from health in-
surance companies and education of patients and physi-
cians. To make the web-based genomic survival analysis
resources accessible to broader communities outside of
biomedical research by integrating them with clinical
decision support system (CDSS) in electronic health
record (EHR) may help resolve these issues and eventually
facilitate clinical translation of genome-based prognostic
biomarkers.
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